Cancer cells process nutrients and energy in different ways to normal cells depending on their underlying molecular profile. This group’s research has discovered a number of metabolic vulnerabilities that have led to new strategies for treating cancer.

The Myeloid Metabolism Group's research program designs innovative methods to identify mutation-specific vulnerabilities in blood cancers including acute myeloid leukaemia.

These methods include lipidomics using primary cell iterative mass spectrometry, targeted drug screening and genome-wide genetic screens, integration of germline genomics with somatic mutations and bioinformatic synthetic lethal prediction tools.

The Myeloid Metabolism Group has identified novel drug targets for common epigenetic mutations in cancer including IDH1, IDH2, WT1, CALR and TET2 mutations.